A review of recent trends and remaining challenges in bispecific antibody (bsAb) production has been published.

Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.

CAMBRIDGE, Mass., February 07, 2025--eGenesis announces second patient successfully transplanted with genetically engineered ...

The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BAT2506 as a biosimilar to reference p ...